Vaxcyte, Inc. (PCVX) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-02-24
How it makes money
It targets the $8 billion pneumococcal market by offering VAX-31, a 31-valent candidate covering 95% of disease strains currently circulating in adults.
The company seeks to disrupt the pneumococcal vaccine market by addressing unmet needs for broader protection. It expects the primary driver of future profit to be the commercialization of its high-valent candidates, particularly VAX-31, which targets 11 more serotypes than current standard-of-care vaccines.
Profitability depends on capturing share in the $8 billion global market by providing protection against approximately 95% of invasive pneumococcal disease strains, an incremental improvement of up to 34% over existing 20-valent options.
What growth costs
It spent $766.6 million in 2025 on research and development, contributing to an accumulated deficit of $2.2 billion while seeking regulatory approvals.
As a clinical-stage entity, the company must dedicate nearly all resources to research, preclinical studies, and advancing candidates through clinical trials. It has no product revenue and expects substantial and increasing losses as it scales manufacturing and clinical activities.
Maintaining the pipeline and achieving commercial viability will require significant additional funding. The company has already accumulated a $2.2 billion deficit to fund these development efforts through December 31, 2025.
What could damage it
Failure to transition from research to commercial-scale manufacturing could permanently prevent it from generating revenue despite its $2.2 billion accumulated deficit.
The business model faces a critical risk in its inability to demonstrate successful commercial-scale production. If the company cannot transition from a research-focused organization to one capable of manufacturing and marketing its vaccines, its multi-billion dollar investment in candidates like VAX-31 could be entirely lost.
Without regulatory approval or the ability to manufacture at scale, the company will continue to incur net losses and may never achieve the profitability required to sustain operations.
About Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.